Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics entities : Nurix therapeutics, inc. save search
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Published: 2024-04-16 (Crawled : 22:00) - globenewswire.com
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: 3.07%
H: 0.79%
C: -6.75%
offering therapeutics
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
Published: 2024-04-12 (Crawled : 04:00) - globenewswire.com
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: -1.32%
H: 2.19%
C: 1.76%
million offering therapeutics
Nurix Therapeutics Announces Proposed Public Offering
Published: 2024-04-11 (Crawled : 20:00) - globenewswire.com
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: -1.32%
H: 2.19%
C: 1.76%
offering therapeutics
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.32%
H: 0.0%
C: 0.0%
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: 18.35%
H: 1.98%
C: -5.88%
first update therapeutics financial results
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
Published: 2024-04-09 (Crawled : 20:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.71%
H: 0.0%
C: 0.0%
ORIC | $9.2 -3.26% -3.37% 670K
|
Health Technology
|
| O: -2.81%
H: 1.54%
C: -3.57%
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: 18.35%
H: 1.98%
C: -5.88%
therapeutics
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
Published: 2024-04-09 (Crawled : 17:00) - globenewswire.com
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: 1.26%
H: 0.0%
C: 0.0%
nx-5948 first cell for therapeutics
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
Published: 2024-04-09 (Crawled : 11:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.38%
H: 0.95%
C: 0.83%
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: 1.26%
H: 0.0%
C: 0.0%
protein collaboration extension therapeutics sanofi
Nurix Therapeutics to Participate in Upcoming Investor Conferences - April 03, 2024
Published: 2024-04-03 (Crawled : 12:00) - biospace.com/
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: -1.28%
H: 0.68%
C: -0.55%
therapeutics
Nurix Therapeutics to Participate in Upcoming Investor Conferences
Published: 2024-04-03 (Crawled : 11:00) - globenewswire.com
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: -1.28%
H: 0.68%
C: -0.55%
therapeutics
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
Published: 2024-04-02 (Crawled : 12:00) - biospace.com/
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: -1.59%
H: 6.37%
C: 4.57%
sciences collaboration extension therapeutics
Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: 0.22%
H: 7.32%
C: 0.59%
cancer international protein therapeutics
Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting
Published: 2024-03-20 (Crawled : 13:30) - globenewswire.com
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: -0.31%
H: 5.98%
C: 4.57%
nx-1607 meeting
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 TrialNurix cleared to introduce new chirally controlled NX-2127 drug product and resume enrollment of new patients into the study
Published: 2024-03-11 (Crawled : 12:30) - biospace.com/
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: 1.14%
H: 4.19%
C: -5.93%
nx-2127 fda cleared drug therapeutics study
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: 1.14%
H: 4.19%
C: -5.93%
nx-2127 fda trial therapeutics
Nurix Therapeutics to Participate in Upcoming Investor Conferences
Published: 2024-03-06 (Crawled : 21:00) - globenewswire.com
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: 0.64%
H: 2.22%
C: -7.99%
therapeutics
Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting
Published: 2024-03-05 (Crawled : 22:00) - globenewswire.com
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: 3.0%
H: 15.94%
C: 13.97%
association cancer research meeting therapeutics
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update
Published: 2024-02-15 (Crawled : 21:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.66%
H: 0.0%
C: -1.59%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: 0.0%
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: -6.09%
H: 9.95%
C: 6.7%
year update therapeutics financial results
Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader
Published: 2024-02-01 (Crawled : 21:00) - globenewswire.com
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: -0.49%
H: 1.48%
C: 0.37%
nx-2127 publication therapeutics
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL
Published: 2024-01-16 (Crawled : 21:00) - globenewswire.com
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: -3.21%
H: 3.32%
C: -0.36%
nx-5948 fda treatment designation therapeutics
Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases
Published: 2024-01-08 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 2.07%
H: 0.48%
C: 0.48%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.16%
H: 0.0%
C: 0.0%
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: -1.01%
H: 2.76%
C: 1.94%
cancer pipeline protein therapeutics
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.